AU2006218489B2 - KIM-1 antibodies for treatment of Th2-mediated conditions - Google Patents

KIM-1 antibodies for treatment of Th2-mediated conditions Download PDF

Info

Publication number
AU2006218489B2
AU2006218489B2 AU2006218489A AU2006218489A AU2006218489B2 AU 2006218489 B2 AU2006218489 B2 AU 2006218489B2 AU 2006218489 A AU2006218489 A AU 2006218489A AU 2006218489 A AU2006218489 A AU 2006218489A AU 2006218489 B2 AU2006218489 B2 AU 2006218489B2
Authority
AU
Australia
Prior art keywords
antibody
seq
antigen
amino acids
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006218489A
Other languages
English (en)
Other versions
AU2006218489A1 (en
Inventor
Veronique Bailly
Alexey Lugovskoy
Patricia Mccoon
Paul D. Rennert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of AU2006218489A1 publication Critical patent/AU2006218489A1/en
Application granted granted Critical
Publication of AU2006218489B2 publication Critical patent/AU2006218489B2/en
Priority to AU2011202405A priority Critical patent/AU2011202405B2/en
Assigned to BIOGEN MA INC. reassignment BIOGEN MA INC. Request to Amend Deed and Register Assignors: BIOGEN IDEC MA INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2006218489A 2005-03-02 2006-03-02 KIM-1 antibodies for treatment of Th2-mediated conditions Ceased AU2006218489B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011202405A AU2011202405B2 (en) 2005-03-02 2011-05-24 KIM-1 Antibodies for Treatment of TH2-mediated Conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65778905P 2005-03-02 2005-03-02
US60/657,789 2005-03-02
PCT/US2006/007441 WO2006094134A2 (en) 2005-03-02 2006-03-02 Kim-1 antibodies for treatment of th2-mediated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011202405A Division AU2011202405B2 (en) 2005-03-02 2011-05-24 KIM-1 Antibodies for Treatment of TH2-mediated Conditions

Publications (2)

Publication Number Publication Date
AU2006218489A1 AU2006218489A1 (en) 2006-09-08
AU2006218489B2 true AU2006218489B2 (en) 2011-02-24

Family

ID=36648475

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006218489A Ceased AU2006218489B2 (en) 2005-03-02 2006-03-02 KIM-1 antibodies for treatment of Th2-mediated conditions
AU2011202405A Ceased AU2011202405B2 (en) 2005-03-02 2011-05-24 KIM-1 Antibodies for Treatment of TH2-mediated Conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011202405A Ceased AU2011202405B2 (en) 2005-03-02 2011-05-24 KIM-1 Antibodies for Treatment of TH2-mediated Conditions

Country Status (14)

Country Link
US (2) US8206705B2 (https=)
EP (2) EP2251037B1 (https=)
JP (2) JP2008531719A (https=)
KR (1) KR101213894B1 (https=)
CN (2) CN103751780A (https=)
AT (1) ATE478707T1 (https=)
AU (2) AU2006218489B2 (https=)
BR (1) BRPI0608254A2 (https=)
CA (1) CA2599967C (https=)
DE (1) DE602006016413D1 (https=)
IL (1) IL185653A (https=)
NZ (1) NZ562045A (https=)
WO (1) WO2006094134A2 (https=)
ZA (1) ZA200708372B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008064031A2 (en) * 2006-11-13 2008-05-29 Government Of The United States, As Represented Bythe Secretary Of The Department Of Health And Human Services Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses
JP6152090B2 (ja) 2011-04-21 2017-06-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 視神経脊髄炎を処置するための組成物および方法
CN108472365A (zh) 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
US10508143B1 (en) 2015-10-30 2019-12-17 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098920A1 (en) * 2001-06-01 2002-12-12 Biogen, Inc. Molecules and methods for inhibiting shedding of kim-1
WO2004060041A2 (en) * 2002-12-30 2004-07-22 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
WO2004084823A2 (en) * 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6165733A (en) 1996-05-23 2000-12-26 Chiron Corporation γ II adaptin
ES2258793T5 (es) 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
EP0948597A4 (en) 1996-11-01 2002-07-10 Human Genome Sciences Inc Human, mucous membrane-specific addressin cell adhesion molecule (MAdCAM-1) and its splice variants
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
ATE346085T1 (de) 1996-12-06 2006-12-15 Vertex Pharma Inhibitoren des interleukin-1-beta konvertierenden enzyms
CN101274962A (zh) 1998-01-23 2008-10-01 霍夫曼-拉罗奇有限公司 人il-12抗体
US6528514B1 (en) 1998-03-11 2003-03-04 Welfide Corporation IgE antibody production inhibitors and autoimmune diseases inhibitors
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
ATE425249T1 (de) 2000-06-16 2009-03-15 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US7553939B2 (en) 2001-06-29 2009-06-30 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
AU2003228336B2 (en) 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
US20050119210A1 (en) 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
KR20070037570A (ko) 2004-03-24 2007-04-05 텔로스 파마슈티칼스 인코포레이티드 백신에 대한 면역반응을 향상시키는 보강제로서의 조성물및 이의 사용 방법
US8025557B2 (en) 2009-02-27 2011-09-27 Illinois Tool Works Inc. Sanding clay

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098920A1 (en) * 2001-06-01 2002-12-12 Biogen, Inc. Molecules and methods for inhibiting shedding of kim-1
WO2004060041A2 (en) * 2002-12-30 2004-07-22 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
WO2004084823A2 (en) * 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Busse, W. et al. 2001 J. Allergy Clin. Immunol. vol. 108, no. 2, pp. 184-190 *

Also Published As

Publication number Publication date
AU2006218489A1 (en) 2006-09-08
KR101213894B1 (ko) 2012-12-20
CN103751780A (zh) 2014-04-30
CA2599967C (en) 2014-10-21
IL185653A (en) 2013-04-30
EP1865985B1 (en) 2010-08-25
US20100150905A1 (en) 2010-06-17
DE602006016413D1 (de) 2010-10-07
HK1118007A1 (en) 2009-01-30
ZA200708372B (en) 2008-12-31
CN101166542A (zh) 2008-04-23
AU2011202405B2 (en) 2013-03-28
NZ562045A (en) 2010-12-24
CA2599967A1 (en) 2006-09-08
JP2008531719A (ja) 2008-08-14
WO2006094134A3 (en) 2006-10-19
JP2012131825A (ja) 2012-07-12
ATE478707T1 (de) 2010-09-15
EP2251037B1 (en) 2015-01-14
EP2251037A1 (en) 2010-11-17
IL185653A0 (en) 2008-01-06
AU2011202405A1 (en) 2011-06-09
BRPI0608254A2 (pt) 2009-12-08
US20130089539A1 (en) 2013-04-11
US8206705B2 (en) 2012-06-26
EP1865985A2 (en) 2007-12-19
KR20070110411A (ko) 2007-11-16
WO2006094134A2 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
US9205148B2 (en) Antibodies and other molecules that bind B7-H1 and PD-1
JP2008510714A (ja) 多発性硬化症の長期処置
EP4200018B1 (en) Anti-par-2 antibodies and methods of use thereof
AU2014233685A1 (en) Anti-CD52 antibodies
AU2011202405B2 (en) KIM-1 Antibodies for Treatment of TH2-mediated Conditions
JP2024538791A (ja) ＩｇＥ介在性疾患の治療
HK1150360A (en) Kim-1 antibodies for treatment of th1/th2-mediated conditions
HK1118007B (en) Kim-1 antibodies for treatment of th2-mediated conditions
WO2006133286A2 (en) Treatment of tnf antagonist-resistant inflammatory disorders and related methods
MX2007010738A (en) Kim-1 antibodies for treatment of th2-mediated conditions
US20090202562A1 (en) Anti-gfralpha3 antibodies
US20230406951A1 (en) Anti-tnfr2 antibodies and methods of use thereof
US20200239562A1 (en) Anti-il-33 therapy for atopic dermatitis
HK40095177B (en) Anti-par-2 antibodies and methods of use thereof
HK40095177A (en) Anti-par-2 antibodies and methods of use thereof
HK1188230B (en) Human oncostatin m antibodies and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired